Article Versions Notes

Pyrpyris N, Dimitriadis K, Kyriakoulis KG, Soulaidopoulos S, Tsioufis P, Papanikolaou A, Baikoussis NG, Antonopoulos A, Aznaouridis K, Tsioufis K. Phenotyping the Use of Cangrelor in Percutaneous Coronary Interventions. Pharmaceuticals. 2025; 18(3):432. https://doi.org/10.3390/ph18030432

Pyrpyris, Nikolaos, Kyriakos Dimitriadis, Konstantinos G. Kyriakoulis, Stergios Soulaidopoulos, Panagiotis Tsioufis, Aggelos Papanikolaou, Nikolaos G. Baikoussis, Alexios Antonopoulos, Konstantinos Aznaouridis, and Konstantinos Tsioufis. 2025. "Phenotyping the Use of Cangrelor in Percutaneous Coronary Interventions" Pharmaceuticals 18, no. 3: 432. https://doi.org/10.3390/ph18030432

Pyrpyris, N., Dimitriadis, K., Kyriakoulis, K. G., Soulaidopoulos, S., Tsioufis, P., Papanikolaou, A., Baikoussis, N. G., Antonopoulos, A., Aznaouridis, K., & Tsioufis, K. (2025). Phenotyping the Use of Cangrelor in Percutaneous Coronary Interventions. Pharmaceuticals, 18(3), 432. https://doi.org/10.3390/ph18030432